Fluoxetine — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Depression

• Citalopram
• Sertraline
• Bupropion XL
• Escitalopram

Also listed for Obsessive-Compulsive Disorder

• Clomipramine
• Fluvoxamine
• Paroxetine

Also listed for Post-Traumatic Stress Disorder

• Prazosin

Other medications in Mental Health

• Fluphenazine
• Gabapentin
• Guanfacine
• Haloperidol
• Iloperidone
• Imipramine
• Isocarboxazid
• Levomilnacipran

What Fluoxetine is approved for (FDA label)

Fluoxetine Capsules are indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [ see Clinical Studies (14.1) ]. Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [ see Clinical Studies (14.2) ]. Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [ see Clinical Studies (14.3) ]. Acute treatment of Panic Disorder, with or without agoraphobia [ see Clinical Studies (14.4) ]. Fluoxetine and Olanzapine in Combination is indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder.

Source: Read the full FDA label on DailyMed. Label effective date: August 11, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Fluoxetine (FDA label)

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS • Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [ see Warnings and Precautions ( 5.1 ) ]. • In patients of all ages who are started on antidepressant therapy, monitor closely for worsening and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [ see Warnings and Precautions ( 5.1 ) ]. • Fluoxetine is not approved for use in children less than 7 years of age [ see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.4 ) ]. When using fluoxetine and olanzapine in combination, also refer to Boxed Warning section of the package insert for Symbyax. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants ( 5.1 ). • Monitor for worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). When using fluoxetine and olanzapine in combination, also refer to Boxed Warning section of the package insert for Symbyax.

Source: FDA prescribing information (DailyMed). Set ID: 6f4e4e9f-9ded-452f-b3ef-ab6aa9c72952. SPL document ID: 202cbd5e-67bd-4cf6-a262-acbca2e42ffe. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Fluoxetine (FDA label)

10 mg Capsule is an opaque green cap and opaque green body, imprinted with HP28 on the cap and on the body in black ink 20 mg Capsule is an opaque green cap and opaque yellow body, imprinted with HP29 on the cap and on the body in black ink 40 mg Capsule is an opaque green cap and opaque orange body, imprinted with HP30 on the cap and on the body in black ink Capsules: 10 mg, 20 mg, 40 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 6f4e4e9f-9ded-452f-b3ef-ab6aa9c72952. SPL document ID: 202cbd5e-67bd-4cf6-a262-acbca2e42ffe. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Fluoxetine (FDA label)

The following adverse reactions are discussed in more detail in other sections of the labeling: Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults [ see Boxed Warning and Warnings and Precautions ( 5.1 ) ] Serotonin Syndrome [ see Warnings and Precautions ( 5.2 ) ] Allergic Reactions and Rash [ see Warnings and Precautions ( 5.3 ) ] Screening Patients for Bipolar Disorder and Monitoring for Mania/Hypomania [ see Warnings and Precautions ( 5.4 ) ] Seizures [ see Warnings and Precautions ( 5.5 ) ] Altered Appetite and Weight [ see Warnings and Precautions ( 5.6 ) ] Increased Risk of Bleeding [ see Warnings and Precautions ( 5.7 ) ] Angle-Closure Glaucoma [ see Warnings and Precautions ( 5.8 ) ] Hyponatremia [ see Warnings and Precautions ( 5.9 ) ] Anxiety and Insomnia [ see Warnings and Precautions ( 5.10 ) ] QT Prolongation [ see Warnings and Precautions ( 5.11 ) ] Potential for Cognitive and Motor Impairment [ see Warnings and Precautions ( 5.13 ) ] Discontinuation Adverse Reactions [ see Warnings and Precautions ( 5.15 ) ] Sexual Dysfunction [ see Warnings and Precautions ( 5.17 ) ] When using fluoxetine and olanzapine in combination, also refer to the Adverse Reactions section of the package insert for Symbyax. Most common adverse reactions (≥5% and at least twice that for placebo) associated with: Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia, and Panic Disorder: abnormal dreams, abnormal ejaculation, anorexia, anxiety, asthenia, diarrhea, dry mouth, dyspepsia, flu syndrome, impotence, insomnia, libido decreased, nausea, nervousness, pharyngitis, rash, sinusitis, somnolence, sweating, tremor, vasodilatation, and yawn ( 6.1 ) Fluoxetine and olanzapine in combination – Also refer to the Adverse Reactions section of the package insert for Symbyax ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 6f4e4e9f-9ded-452f-b3ef-ab6aa9c72952. SPL document ID: 202cbd5e-67bd-4cf6-a262-acbca2e42ffe. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Fluoxetine (FDA label)

When using fluoxetine and olanzapine in combination, also refer to the Contraindications section of the package insert for Symbyax. Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with fluoxetine or within 5 weeks of stopping treatment with fluoxetine. Do not use fluoxetine within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start fluoxetine in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 ) Pimozide: Do not use. Risk of QT prolongation and drug interaction ( 4.2 , 5.11 , 7.7 , 7.8 ) Thioridazine: Do not use. Risk of QT interval prolongation and elevated thioridazine plasma levels.

Source: FDA prescribing information (DailyMed). Set ID: 6f4e4e9f-9ded-452f-b3ef-ab6aa9c72952. SPL document ID: 202cbd5e-67bd-4cf6-a262-acbca2e42ffe. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Fluoxetine (FDA label)

When using fluoxetine and olanzapine in combination, also refer to the Warnings and Precautions section of the package insert for Symbyax. Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults: Monitor for clinical worsening and suicidal thinking and behavior ( 5.1 ) Serotonin Syndrome: Serotonin syndrome has been reported with SSRIs and SNRIs, including fluoxetine, both when taken alone, but especially when co-administered with other serotonergic agents. If such symptoms occur, discontinue fluoxetine and serotonergic agents and initiate supportive treatment.

Source: FDA prescribing information (DailyMed). Set ID: 6f4e4e9f-9ded-452f-b3ef-ab6aa9c72952. SPL document ID: 202cbd5e-67bd-4cf6-a262-acbca2e42ffe. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Fluoxetine (FDA label)

As with all drugs, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic, pharmacokinetic drug inhibition or enhancement, etc.) is a possibility.

Source: FDA prescribing information (DailyMed). Set ID: 6f4e4e9f-9ded-452f-b3ef-ab6aa9c72952. SPL document ID: 202cbd5e-67bd-4cf6-a262-acbca2e42ffe. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.